Diabetic Patients

esperion

Esperion Reports Cholesterol Cut Up To 43% In Diabetics On New Drug

Esperion Therapeutics’ proposed new cholesterol-busting drug cut the level of low-density lipoprotein, the so-called bad choleterol, up to 43 percent in a Phase 2 test of diabetic patients.

WWJ Newsradio 950–05/02/2013

Follow

Get every new post delivered to your Inbox.

Join 2,345 other followers